Skip to content

Discussion on the multidisciplinary Management Model of Portal hypertension in Liver Cirrhosis and Analysis of Its Prognostic Influencing factors

Discussion on the multidisciplinary Management Model of Portal hypertension in Liver Cirrhosis and Analysis of Its Prognostic Influencing factors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127936
Enrollment
Unknown
Registered
2026-07-10
Start date
2026-07-10
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhotic portal hypertension

Interventions

MDT execution group (observation group):NA
MDT non execution group (control group):NA

Sponsors

The third people's hospital of Shenzhen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosed with cirrhosis through imaging examination, endoscopy, or pathological analysis; 2.Patients undergoing routine clinical examinations including multi-slice spiral CT and HVPG pressure measurement; 3.Between the ages of 20 and 80; 4.Our clinical data is complete;

Exclusion criteria

Exclusion criteria: 1.Senior (over 80 years old) or minor (under 20 years old); 2.Patients with liver cirrhosis who have not experienced clinical manifestations of portal hypertension (such as variceal bleeding, ascites, etc.) or HVPG measurement<5mmHg; 3.Patients with missing data in blood biochemical indicators, upper abdominal enhanced CT, and hepatic vein pressure gradient (HVPG) measurements; 4.Patients who have recently been treated with non selective receptor blockers; 5.There are factors that can cause deterioration of liver function; 6.Patients with liver malignant tumors or other advanced malignant tumors; 7. Patients with severe heart failure, uremia, cerebral infarction, respiratory failure, and other diseases; 8. HIV patients; 9. Pregnancy.

Design outcomes

Primary

MeasureTime frame
Die;

Secondary

MeasureTime frame
Hepatic encephalopathy status;Gastrointestinal bleeding situation;Occurrence of liver cancer;

Countries

China

Contacts

Public ContactLai Changxiang

The third people's hospital of Shenzhen

807874297@qq.com+86 755 6122 2333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026